Stereotactic body radiation therapy (SBRT) has emerged as an effective option for the treatment of localized prostate cancer; however, data from real-world clinical practice remain limited.
Between January 2020 and December 2023, 251 patients with localized prostate cancer treated with SBRT were included in 12 centers in Spain.
The treatment volume included prostate +/- seminal vesicles, without prophylactic pelvic radiotherapy. A dose of 35-40 Gy was prescribed in 5 fractions, every other day. Acute genitourinary (GU), gastrointestinal (GI) and sexual toxicity was assessed up to 6 months post-treatment using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
A total of 251 patients were classified based on the National Comprehensive Cancer Network (NCCN®) classification. Four percent of patients had very low-risk disease, 26.3% low-risk, and 66.5% intermediate-risk (27.1% favorable intermediate and 39.4% unfavorable intermediate). Additionally, 2.8% were classified as high-risk and 0.4% as very high-risk. The median patient age was 72 years (range: 65-76), and the baseline PSA was 6.7 ng/mL (range: 5.3-8.7). The median SBRT dose was 40 Gy (range: 35-40 Gy). Grade 2 acute GU toxicity occurred in 6.4% of patients, and grade 3 in 0.4%. Grade 2 GI toxicity was observed in 0.8%, with no cases of grade 3 GI toxicity. Regarding sexual toxicity, 11.2% of patients experienced grade 2, and 1.2% grade 3 toxicity.
Five-fraction SBRT is a feasible and safe treatment with a low incidence of acute toxicity.
Actas urologicas espanolas. 2025 Jul 07 [Epub ahead of print]
S E Romero Zoghbi, F López Campos, D Sanz-Rosa, J Fernández Ibiza, I J Thuissard-Vasallo, C Andreu-Vázquez, C Laria, J Andreescu Yagüe, E Krumina, A Ocanto, M Mateos, L A Glaría, J A García Cuesta, D Gonsalves, C Fernández, D Esteban, J Begara de la Fuente, D Rivas, E López Ramírez, L Aakki, J A González Ferreira, A Ristori, A B Bezares Alarcón, L Larrea, R García García, F Couñago
Servicio de Oncología Radioterápica, GenesisCare Talavera de la Reina, Talavera de la Reina, Toledo, Spain; Escuela de Doctorado e Investigación, Universidad Europea de Madrid, Madrid, Spain. Electronic address: ., Servicio de Oncología Radioterápica, Hospital Universitario Ramón y Cajal, Madrid, Spain; Servicio de Oncología Radioterápica, GenesisCare Madrid, Hospital Universitario La Milagrosa, Madrid, Spain., Departamento de Medicina, Facultad de Medicina, Salud y Deportes, Universidad Europea de Madrid, Madrid, Spain., Servicio de Oncología Radioterápica, Centro 360 de Excelencia Oncológica GenesisCare Clínica Corachan, Barcelona, Spain., Departamento de Veterinaria, Facultad de Ciencias Biomédicas y de la Salud, Universidad Europea de Madrid, Madrid, Spain., Servicio de Oncología Radioterápica, GenesisCare Talavera de la Reina, Talavera de la Reina, Toledo, Spain., Servicio de Oncología Radioterápica, GenesisCare Córdoba, Córdoba, Spain., Servicio de Oncología Radioterápica, GenesisCare Guadalajara, Guadalajara, Spain., Escuela de Doctorado e Investigación, Universidad Europea de Madrid, Madrid, Spain; Servicio de Oncología Radioterápica, GenesisCare Madrid, Hospital Universitario La Milagrosa, Madrid, Spain; Servicio de Oncología Radioterápica, GenesisCare Madrid, Hospital Universitario San Francisco de Asís, Madrid, Spain., Servicio de Oncología Radioterápica, GenesisCare Madrid, Madrid, Spain., Servicio de Oncología Radioterápica, GenesisCare Madrid, Hospital Universitario La Milagrosa, Madrid, Spain; Servicio de Oncología Radioterápica, Hospital Universitario La Paz, Madrid, Spain., Servicio de Oncología Médica, GenesisCare Madrid, Hospital Universitario San Francisco de Asís, Madrid, Spain., Servicio de Oncología Radioterápica, GenesisCare Madrid, Hospital Universitario La Milagrosa, Madrid, Spain; Servicio de Oncología Radioterápica, GenesisCare Madrid, Hospital Universitario San Francisco de Asís, Madrid, Spain., Servicio de Oncología Radioterápica, GenesisCare Alcázar de San Juan, Alcázar de San Juan, Ciudad Real, Spain., Servicio de Oncología Radioterápica, Centro de Excelencia GenesisCare Málaga, Málaga, Spain., Servicio de Oncología Radioterápica, GenesisCare Alicante, Alicante, Spain., Servicio de Oncología Radioterápica, GenesisCare Sevilla, Sevilla, Spain., Servicio de Oncología Radioterápica, GenesisCare Jerez de la Frontera, Jerez de la Frontera, Cádiz, Spain., Servicio de Oncología Radioterápica, GenesisCare Campo de Gibraltar, Algeciras, Cádiz, Spain., Servicio de Oncología Radioterápica, GenesisCare Hospital Vithas Valencia Consuelo, Valencia, Spain., Servicio de Oncología Radioterápica, Hospital Ruber Internacional, Madrid, Spain., Servicio de Oncología Radioterápica, GenesisCare Madrid, Hospital Universitario La Milagrosa, Madrid, Spain; Departamento de Medicina, Facultad de Medicina, Salud y Deportes, Universidad Europea de Madrid, Madrid, Spain; Servicio de Oncología Radioterápica, GenesisCare Madrid, Hospital Universitario San Francisco de Asís, Madrid, Spain.
PubMed http://www.ncbi.nlm.nih.gov/pubmed/40633664